---
title: Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
nct_id: NCT00568984
overall_status: COMPLETED
phase: PHASE4
sponsor: Novo Nordisk A/S
study_type: INTERVENTIONAL
primary_condition: Diabetes
countries: China, Malaysia, Philippines, Thailand
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00568984.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00568984"
ct_last_update_post_date: 2017-02-20
last_seen_at: "2026-05-12T06:41:52.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

**Official Title:** Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes Mellitus

**NCT ID:** [NCT00568984](https://clinicaltrials.gov/study/NCT00568984)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 324
- **Lead Sponsor:** Novo Nordisk A/S
- **Conditions:** Diabetes, Diabetes Mellitus, Type 2
- **Start Date:** 2002-11-21
- **Completion Date:** 2003-11-10
- **CT.gov Last Update:** 2017-02-20

## Brief Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 99 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Type 2 diabetes for at least 3 months
* No previous treatment for diabetes
* HbA1c between 7.0-12.0%
* Body Mass Index (BMI) between 19.0-40.0 kg/m2

Exclusion Criteria:

* Type 1 diabetes
* Known unstable/untreated proliferative retinopathy
* Uncontrolled treated/untreated hypertension
* Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
```

## Interventions

- **repaglinide** (DRUG)
- **metformin** (DRUG)
- **glicazide** (DRUG)

## Primary Outcomes

- **HbA1c** _(time frame: after 16 weeks of treatment)_

## Secondary Outcomes

- **Glucose profiles**
- **Quality of life assessment**
- **Treatment satisfaction**
- **Hypoglycaemic events**
- **Adverse events**

## Locations (15)

- Novo Nordisk Investigational Site, Beijing, Beijing Municipality, China
- Novo Nordisk Investigational Site, Beijing, Beijing Municipality, China
- Novo Nordisk Investigational Site, Beijing, Beijing Municipality, China
- Novo Nordisk Investigational Site, Tianjin, Tianjin Municipality, China
- Novo Nordisk Investigational Site, Cheras, Malaysia
- Novo Nordisk Investigational Site, Ipoh, Malaysia
- Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia
- Novo Nordisk Investigational Site, Cebu City, Philippines
- Novo Nordisk Investigational Site, Manila, Philippines
- Novo Nordisk Investigational Site, Marikina City, Philippines
- Novo Nordisk Investigational Site, Pampanga, Philippines
- Novo Nordisk Investigational Site, Quezon, Philippines
- Novo Nordisk Investigational Site, Quezon City, Philippines
- Novo Nordisk Investigational Site, Bangkok, Thailand
- Novo Nordisk Investigational Site, Bangkok, Thailand

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|beijing|beijing municipality|china` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|tianjin|tianjin municipality|china` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|cheras||malaysia` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|ipoh||malaysia` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|kota bharu, kelantan||malaysia` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|cebu city||philippines` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|manila||philippines` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|marikina city||philippines` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|pampanga||philippines` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|quezon||philippines` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|quezon city||philippines` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|bangkok||thailand` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00568984.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00568984*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*